143 PROMIS in VWD, IPFDs and RBDs 5 funding/educational and travel funding from the following companies over the years: het Sikkelcelfonds, Pfizer, Baxter/Baxalta/Shire Takeda, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, Nordic Pharma and Roche, and has served as a member on steering boards of Roche and Bayer. All grants, awards and fees go to the Erasmus MC as an institution. S.C. Gouw has received an unrestricted research grant from Sobi. All other authors have no competing interest relevant to the contents of this manuscript. Funding This study was performed on behalf of the SYMPHONY consortium (NWA.1160. 18.038.) which is funded by a grant from the Netherlands Organization for Scientific Research (NWO). Ethics statement The Medical Research Ethical Committee of the Radboud university medical center (MREC Oost-Nederland) reviewed the study protocol and determined it to be exempt from the Medical Research Involving Human Subjects Act (WMO) (MEC-2022-13847). In addition, this study was included within an amendment of the original von Willebrand in the Netherlands – Prospective (Win-Pro) study and Thrombocytopathy in the Netherlands (TiN) study. These amendments were reviewed and approved by respectively the Medical Research Ethics Committee of the Erasmus Medical Center Rotterdam and the Medical Research Ethics Committee of the University Medical Center Utrecht (MREC NedMec). All procedures performed in this study were in accordance with the ethical standards of the international and or/national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Acknowledgements The SYMPHONY consortium, which aims to orchestrate personalized treatment in patients with bleeding disorders, is a unique collaboration between patients, health care professionals and translational and fundamental researchers specialized in inherited bleeding disorders, as well as experts from multiple disciplines. SYMPHONY aims to identify best treatment choice for each individual based on bleeding phenotype. In order to achieve this goal, workpackages have been organized according to three themes e.g. Diagnostics (workpackage 3&4), Treatment (workpackages 5-9) and Fundamental Research (workpackages 10-12). Principal investigator: Dr. M.H. Cnossen. Project manager: Dr. S.H. Reitsma. More information: www.symphonyconsortium.nl.
RkJQdWJsaXNoZXIy MTk4NDMw